Atoguanil

Ipca
Chemoprevention
Intermittent preventative treatment (TPP-1)
Chemoprophylaxis (TPP-2)

Atoguanil

Translational
-
Human volunteers
Product vision
  • Intermittent preventive treatment and chemoprevention
MOA
  • Atocaquone and proguanil interfere with two pathways involved in the biosynthesis of pyrimidines required for nucleic acid replication. 
  • Atovaquone acts against P. falciparum via inhibition of mitochondrial electron transport
Key features
  • Liver-stage activity and prophylactic efficacy
  • Lower doses of atovaquone required in the combination leading to lower cost of goods
Challenges
  • Obtaining comparable bioavailability to atovaquone-proguanil with half the atovaquone dose
  • Obtaining cost of goods suitable for chemoprevention
Status
  • Relative bioavailability study between atoguanil and atovaquone-proguanil completed
  • Programme terminated 
Next milestone
  • N/A
Project Director
  • Dr Isabelle Borghini-Fuhrer